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Abstract

Introduction
Traumatic brain injury (TBI) is a significant cause of disability and death and a huge economic burden throughout the world. Much of the morbidity associated with TBI is attributed to secondary brain injuries resulting in hypoxia and ischaemia after the initial trauma. Intracranial hypertension and decreased partial brain oxygen tension (PbtO2) are targeted as potentially avoidable causes of morbidity. Therapeutic hypothermia (TH) may be an effective intervention to reduce intracranial pressure (ICP) but could also affect cerebral blood flow. 
Methods
This is a retrospective analysis of prospectively collected data from 17 patients admitted to the Western General Hospital, Edinburgh. Patients with an ICP >20 mmHg refractory to initial therapy were randomised to standard care or standard care and TH (intervention group) titrated between 32-35°C to reduce ICP. ICP and PbtO2 were measured using the Licox system and core temperature was recorded via rectal thermometer. Data was analysed at the hour prior to cooling; the first hour at target temperature; two consecutive hours at target temperature and after six hours of hypothermia.  
Results
There was a mean decrease in ICP of 4.3 ± 1.6mmHg (p<0.04) from 15.7 to 11.4mmHg, from pre-cooling to the first epoch of hypothermia in the intervention group (n=9) that was not seen in the control group (n=8). A decrease in ICP was maintained throughout all time periods. There was a mean decrease in PbtO2 of 7.8 ± 3.1mmHg (p<0.05) from 30.2 to 22.4mmHg, from pre-cooling to stable hypothermia which was not seen in the control group. 
Conclusions
This research supports others in demonstrating a decrease in ICP with temperature, which could facilitate a reduction in the use of hyperosmolar agents or other stage II interventions. The decrease in PbtO2 is not below the suggested treatment threshold of 20 mmHg, but might indicate a decrease in cerebral blood flow. 


















Introduction 
Traumatic brain injury (TBI) is a significant cause of disability and death and a huge economic burden on our society. The incidence of TBI is rising throughout the world and the World Health Organisation estimates that TBI will become a primary cause of death by the year 2020 (Hyder, 2007). In the US, approximately 1.7 million people suffer a TBI each year. Approximately 52,000 of these die and of those that survive to discharge, 43% have an ongoing disability one year after injury (Corrigan, 2010; Langlois, 2006). The financial cost of TBI in the US in the year 2000 was estimated to be $406 billion (Corso, 2006). In Europe there is an annual incidence of about 235 per 100,000 people and there are approximately 7.7 million people suffering with disabilities due to TBI (Tagliaferri, 2006). 
Much of the morbidity of TBI is attributed to secondary injuries, which occur after the initial injury and are associated with a failure to maintain adequate oxygen delivery to the injured brain (Chesnut, 1995; Chesnut, 1993). As part of the management of secondary brain injury, the Brain Trauma Foundation (BTF) guidelines from 2007 advocate intracranial pressure (ICP) monitoring and maintaining an ICP below a threshold of 20-25mmHg (Brain Trauma Foundation, 2007). This is based upon evidence demonstrating worse outcomes in patients with intracranial hypertension above this threshold (Brain Trauma Foundation, 2007; Romner, 2013; Zeng, 2014). In addition to monitoring ICP, many centres monitor partial brain oxygen tension (PbtO2), a marker of the oxygen available in the brain for adenosine-triphosphate production, which also reflects the balance between oxygen delivery and consumption (De Georgia, 2014). Both raised ICP and low PbtO2 have been shown to be independent predictors of poor prognosis in severe TBI and BTF guidelines advocate initiating therapy to increase P​btO2 if it falls below 15mmHg (Chang, 2009; Jaeger, 2010; Jaeger, 2006; Jaeger, 2007; Oddo, 2011). However, contemporary articles suggest a threshold of 20mmHg may be more beneficial (Chang, 2009; Longhi, 2007; Oddo, 2011; Oddo 2014 ; Le Roux 2014).
Therapeutic hypothermia (TH), the controlled lowering of core body temperature below 36°C, is currently used as a treatment modality for neonatal hypoxic ischaemic encephalopathy and post-cardiac arrest (Arrich, 2009; NICE, 2011). There is also emerging evidence that it may be beneficial in the management of ischaemic stroke (van der Worp, 2010). Despite conflicting evidence, TH is often used in ICUs to manage patients following severe TBI (Crossley, 2014; Hutchinson, 2013; Sydenham, 2009). Neither the 2007 BTF guidelines nor a Cochrane review from 2009 support the use of TH in the management of severe TBI (Brain Trauma Foundation, 2007; Sydenham, 2009). However, a recent systematic review by Crossley et al. found some evidence to suggest that TH may be of benefit in the management of TBI (Crossley, 2014). Both the Cochrane review and the review by Crossley et al. note that the evidence to support TH comes from low quality trials, which have a tendency to overestimate the treatment effect, and state the need for more high quality trials. 
The Eurotherm3235 trial is a pragmatic multi-centre randomised controlled trial investigating the effects of TH (32-35°C) on outcome after TBI. TH is titrated to reduce ICP in patients following TBI who have an ICP >20mmHg refractory to stage one treatment (see figure 1) (Andrews, 2012; Andrews, 2011). Participants are randomised to either a control or intervention group and receive standard care without TH or standard care with TH respectively as per the Eurotherm3235 trial protocol (Andrews, 2011). 
This study reports the retrospective analysis of prospectively collected data from the first 17 patients enrolled on the Eurotherm3235 trial in Edinburgh who were monitored using the Licox system. We examined the effect of induction of TH on ICP and PbtO2. 





Materials and Methods

Ethical Approval and Consent
Ethical approval for the Eurotherm3235 trial was granted by the Scotland A Research Ethics Committee. Full consent was obtained from/for all patients, copies of which are retained within the patient’s hospital notes and the Welcome Trust Clinical Research Facility, Edinburgh. The trial has been conducted in accordance with Good Clinical Practice guidelines. 

Study Design and Patient Selection
The study was a retrospective analysis of prospectively collected data from the first 17 patients enrolled into the Eurotherm3235 trial at the Western General Hospital, Edinburgh. This is a subgroup analysis of patients who received Licox monitoring from a single centre, hence the small study number. Analysis of the Eurotherm3235 trial is ongoing but does not include multi-centre analysis of PbtO2. Patients were randomised to standard treatment based on the 2007 BTF guidelines or standard treatment and therapeutic hypothermia by an online randomisation service (www.eurotherm3235trial.eu) as soon as possible after meeting the inclusion/exclusion criteria. Inclusion criteria allowed those less than 72 hours following TBI with a primary closed brain injury and an ICP > 20 mmHg refractory to stage one treatment without obvious reversible causes and with an abnormal CT head scan (see figure 1). We excluded hypothermic patients (<36°C); those already receiving cooling therapy; those receiving barbiturates prior to randomisation and patients unlikely to survive the next 24 hours in the opinion of the admitting neurosurgeon. Patients were managed according to the 2007 BTF guidelines, intubated and ventilated to achieve a PaCO2 of 4.5 to 5.0 kPa, sedated and nursed with 30 degree head elevation. Cerebral perfusion pressure was maintained at ≥ 60 mmHg by manipulating mean arterial pressure with fluids and noradrenaline and limiting ICP ≤ 20 mmHg. Hypothermia was initiated in the intervention group with 20-30 ml/kg of refrigerated 0.9% saline given intravenously and maintained with cooling blankets to an initial target temperature of 35°C. If ICP was not maintained below 20mmHg, the depth of cooling was increased in 0.5°C increments to a maximum depth of 32°C. TH was maintained for a minimum of 48 hours and continued until ICP was no longer dependent upon hypothermia. 
Refractory intracranial hypertension in either group lead to an escalation of therapy, including the use of 125mls of 5% Sodium Chloride or 200mls of 20% mannitol as a bolus injection. Paralysis, further CT imaging and surgical intervention were also available. 
Pyrexia in the control group (>38°C) was managed with paracetamol and cooling to normothermia (36.5-37.5°C). All patients received seizure prophylaxis with a loading dose of Phenytoin (20mg/kg) and a maintenance dose (4-5mg/kg) for seven days post-injury.  A comprehensive protocol was used to prevent and treat shivering in the cooled patients. Regular paracetamol was administered to patients and their peripheries were wrapped. Counter-current surface warming and clonidine were both available according to the protocol and persistent shivering was not common in the Edinburgh centre. 
A Licox monitor (Integra, Lyon, France) recorded ICP, PbtO2, and brain temperature via fibre optic pressure catheter, oxygen electrode and thermistor respectively. The Licox probe was inserted into the brain parenchyma via a dedicated triple-lumen bolt which was placed via a burr hole. The bolt was placed so that the monitors were inserted into the front white matter, in the non-dominant hemisphere for diffuse injuries or on the side of maximal injury in focal injuries. The probe was not placed in non-viable tissue. Core body temperature was measured via rectal thermometer. ICU Pilot software (CMA, Sweden) integrated data from the monitors to a bedside computer each minute until ICP monitoring was considered no longer required. See figure 2 for study flow-chart.
Data and Statistical Analysis
The first two hours of PbtO2 data recorded were not included in the analysis to reduce artefact from the Licox monitor (De Georgia, 2014; Geukens & Oddo, 2012). Data from 17 patients, 9 intervention and 8 controls, were analysed at four time-points: Time 0, the hour prior to randomisation (induction of cooling or control); Time 1, the first hour of hypothermia (<35°C); Time 2, the first episode of stable hypothermia (<35°C), defined as two consecutive hours of hypothermia; and Time 3, six hours of stable hypothermia. Values are given as the mean ± standard error of the mean unless otherwise stated. One-way repeat measures of variance (ANOVA) were performed to identify differences within each group and paired student T-tests were performed to identify differences within the groups at the set time points. Independent Student T-tests were performed to identify differences between the groups. All statistical tests were performed using Statistical Package for Social Sciences 20.0 (SPSS version 20, IBM Inc., Armonk, NY, USA).
Results
Control Group Demographics
The mean age of the participants was 34 years. All 8 participants were male. Three patients suffered extradural haemorrhages as their primary injury, two subdural haemorrhages, two traumatic subarachnoid haemorrhages and one patient suffered a diffuse injury. Three participants had non-depressed skull fractures. The median GCS on admission to the emergency department was 7 (range 3-14, see table 1). 
Intervention Group Demographics
The mean age of the participants was 41 years. Two participants were female, seven were male. Three patients suffered EDH as their primary injury, three had diffuse injuries, one had contusions and one had diffuse injuries and a SDH. Five patients had non-depressed skull fractures and one patient had a depressed skull fracture. The median GCS on admission to the emergency department was 7 (range 3-14, see table 1). 
Time to Target Temperature, Haemoglobin, FiO​2, PaO2 and PaCO2
The mean time to target temperature (<35°) in the intervention group was 7 hours (421 ± 72 minutes) after randomisation, due to long lead times to initiation of TH following pre-randomisation hypertonic therapy. 
There was no significant change in FiO2 from pre-cooling to target temperature in the intervention group (median 0.35 (0.30 to 0.55) versus 0.30 (range 0.30 to 0.55) P > 0.05) and there was no significant difference in FiO2 between the two groups. PaO2 and PaCO2 values were not significantly different from pre-cooling to target temperature: Pre-cooling PaO2 16.1 ± 0.9, target temperature 16.3 ± 1.6 kPa, P > 0.05; pre-cooling PaCO2 4.5 ± 0.1, target temperature 4.5 ± 0.2 kPa, P > 0.05. Nor was there a statistically significant difference in PaO2 or PaCO2 values between the two groups. Haemoglobin values were not significantly different between intervention and control groups and were not different at pre-cooling to target temperature in the intervention group (10.1 ± 0.4 versus 9.7 ± 0.4, P > 0.05).
There was no significant difference in the number of osmotic agents used between the control and intervention groups (1, range 0 to 4 and 0 to 5 respectively, p >0.05).      
Intracranial Pressure
In the intervention group the ICP decreased by a mean of 4.3 ± 1.6mmHg (p<0.04) from 15.7 to 11.4mmHg from Time 0 to Time 1 (see figures 3 and 4). This decrease in ICP was maintained from Time 0 to Times 2 and 3. A one-way repeat-measures ANOVA in the intervention group was consistent with these results: F(3, 24)=6.13, p<0.01. There was no statistically significant difference in ICP in the control group between these times. A two-way repeat measures ANOVA reveals a difference between the two groups at these time points: F(3,45)=4, p<0.02.  
Partial Brain Oxygen Tension
Paired T-tests demonstrated a statistically significant difference between Time 0 and Time 2 where there was a mean decrease in PbtO2 of 7.8 ± 3.1mmHg (p<0.05) from 30.2 to 22.4mmHg (see figure 5). A one-way repeat measures ANOVA for the intervention group also showed a difference in PbtO2 with time F(3,18) 4.60, p<0.02. Three patients in the intervention group had a decrease in PbtO2 from >25mmHg at Time 0 to <20mmHg at Time 3.
There was no statistically significant difference between Time 0 and any other times in the control group. However, Paired T-tests demonstrated a mean decrease of 3.47 ± 1.02mmHg (p<0.02) between Time 1 and Time 3, and a mean decrease of 3.48 ± 1.27mmHg (p<0.03) between Time 2 and Time 3 in the control group (see figure 6). There was no statistically significant difference between the two groups in term of the change in PbtO2 (see figure 7).
Discussion
Intracranial Pressure
Starting ICP in this report was less than 20mmHg (ET3235Trial protocol) because a single hypertonic treatment was given pending randomisation and which also resulted in long lead times to initiation of cooling. TH reduced ICP by a mean of 4.3 ± 1.6mmHg from pre-cooling to the first episode of stable hypothermia (~27%), despite pre-treatment with hypertonic therapy. The reduction in ICP was maintained at six hours and there was no further decrease with prolonged hypothermia, which is consistent with previous studies (Schwab, 1998; Shiozaki, 1993). This is a comparable reduction to mannitol and hypertonic saline, which are reported to reduce ICP by 10-51% and have similar efficacy (Berger, 1995; Freshman, 1993; James, 1980; James, 1977; Qureshi, 1998; Qureshi, 1999; Sorani, 2008). Neither of these therapies are without risk. Reported adverse effects of mannitol include renal failure, electrolyte abnormalities, acidosis, hypotension and congestive heart failure. Reported adverse effects of hypertonic saline include renal failure and electrolyte abnormalities in addition to other theoretical concerns (Torre-Healy, 2012). Furthermore, hyperosmolar therapy is limited in that mannitol leads to a short-lived reduction in ICP with diminishing returns and the prolonged use of hypertonic saline over 72 hours has been shown to increase mortality (James, 1977; McGraw, 1999). Therefore, TH may be beneficial in providing a persistent reduction of ICP. It is not suggested that TH is used as an alternative to hyperosmolar therapies, but rather that it may help to reduce the number of therapies required when used in combination. TH however, is not a risk-free intervention either, and can be associated with a number of adverse effects including arrhythmias, electrolyte disturbances and pneumonia. Whilst pneumonia is often reported following TH, a Cochrane review from 2009 found that the trend towards an increased risk of pneumonia was not significant and the quality of evidence supporting it was poor (Sydenham, 2009). 
This study supports others in finding that TH reduces ICP but it does not suggest that outcomes are improved or that the use of hyperosmolar agents is reduced (see Table 2). We await the full analysis of the Eurotherm3235 trial that will conclusively demonstrate whether TH improves outcomes or not.  
Partial Brain Oxygen Tension
Both groups in this report demonstrated a decrease in PbtO2 with time. In the intervention group there was a significant decrease of 7.8 ± 3.1mmHg from 30.2 to 22.4mmHg. In the control group, no statistically significant decrease was seen from Time 0 to any other time points. However, it is worth noting that half of the control group were not included in the Time 0 analysis due to missing data (n=4/8). The first two hours of data from randomisation was not included in analysis because it coincided with the time we allowed for the oxygen electrode to stabilise. In the remaining patients, PbtO2 recording was already in place prior to randomisation and the data was able to be included. There was a statistically significant decrease in PbtO2 in the control group between Time 1 and 3 and Time 2 and 3 of 3.47 ± 1.02mmHg and 3.48 ± 1.27mmHg respectively. It could be that a statistically significant difference between Time 0 and the other time periods would have been seen if all data were present at time 0. There was no statistically significant difference between the two groups.
Previous studies have investigated the effect of hypothermia on PbtO2 with conflicting results. In 2002, Gupta et al. saw a decrease in PbtO2 in a study of 30 patients cooled to a minimum of 33°C and concluded that decreasing brain temperature below 35°C may impair brain tissue oxygenation (Gupta, 2002). However, it has been argued that the Paratrend 7 (Diametrics Medical, High Wicombe, UK) sensor used to measure PbtO2 in this study was not corrected for temperature and so did not reflect an accurate PbtO2. In contrast, Zhang et al. found that mild hypothermia (31.5-34.9°C) increased mean (SD) PbtO2 from 9.6 (6.8) mmHg to 28.7 (8.8) mmHg in 18 patients with severe TBI (Zhang, 2002). Patients in this study received TH within 20 hours following TBI and had PbtO2 recorded within the first 24 hours. Given the very low initial PbtO2 and subsequent increase within 24 hours following injury, it has been suggested that this increase was attributable to early changes in cerebral blood flow (CBF) rather than an effect of hypothermia (Andrews, 2003). 
Decreases in PbtO2 have been associated with poor outcomes independent of raised ICP and the combination of both a raised ICP and decreased PbtO2 appears worse than intracranial hypertension in isolation (Chang, 2011). Normal levels of PbtO2 in neurosurgical patients are reported as between 23-35 mmHg, with lower values coming from probes sited deeper in brain tissue (Dings, 1998; Hoffman, 1996; Pennings, 2008). Whilst the decrease of PbtO2 in the intervention group is significant, the mean value did not decrease below the threshold of 15mmHg recommended for intervention by the 2007 BTF guidelines (Brain Trauma Foundation, 2007). Nor did it decrease below 20mmHg, the suggested threshold for compromised brain oxygen/moderate brain hypoxia (Le Roux, 2014). However, when looking at the individual value plots (see Figure 8) for the intervention group, one can see that 3 participants demonstrated a change in PbtO2 from above 25mmHg prior to cooling to less than 20mmHg after six hours of target temperature. It is unclear why certain patients exhibit this decrease in PbtO2 whilst others do not, but further investigation is warranted to identify those patients likely to benefit most from truly targeted temperature management. 
Arterial blood gases were analysed using the alpha stat method to maintain autoregulation and which was consistent with current practice in the units that participated in the trial. This approach has been undertaken in other contemporary hypothermia trials, such as NABISH II and TTM (Clifton, 2011; Nielson, 2013). Despite this, there was no significant difference in our pre-cooling and target temperature PaCO2 and PaO2 values, which is important given the dependence of PbtO2 upon systemic oxygenation and transport (Rosenthal, 2008). Therefore, the decrease in PbtO2 may be due to reduced CBF secondary to CO2 solubility suggesting that partial pressures decrease with temperature. 
Anaemia has been associated with a decrease in PbtO2 following TBI (Oddo 2012). The current study found no difference in haemoglobin levels either between the two groups, or in the intervention group at pre-cooling or target temperature to account for the change in PbtO2. The haemoglobin of two patients in the control group and three patients in the intervention group was < 9 g/dl, the level at which PbtO2 is thought to be compromised (Oddo, 2012). However, in those randomised to the intervention group, the decreased haemoglobin was present before the patients reached the target temperature.
Balancing Oxygen Delivery with Demand
Tokutomi et al. have previously studied the optimal temperature to reduce ICP whilst resulting in minimal unfavourable outcomes in patients with TBI and concluded that this temperature is about 35°C (Tokutomi, 2003). In their study from 2002, decreases in ICP were most noticeable between 35-36°C and the incidence of jugular venous bulb oxygen desaturation was also decreased at these temperatures. However, oxygen consumption, measured via indirect calorimetry, and oxygen delivery, also progressively decreased. Below 35°C Tokutomi et al. found that oxygen delivery decreased more than the decrease in oxygen demand resulting in an overall deficit. 
A partial explanation for the decrease in ICP with hypothermia is a decrease in CBF, which could also explain the decrease in oxygen delivery (Marion, 1993; Shiozaki, 1993). Hypothermia is thought to decrease cerebral metabolic rate for oxygen (CMRO2) and there may be an associated decrease in oxygen demand (Keller, 1993). Whilst we believe we can reduce ICP and CMRO2, perhaps we are yet to find the balance between decreasing CBF/ICP and maintaining adequate oxygen delivery and are causing unwanted decreases in PbtO2 because of this. 
Limitations of the Study
The present study has some limitations that need to be considered. Due to the nature of the patient population and TH, it is not possible to blind researchers from the administration of TH. In addition, the researchers were not blinded for the analysis of the two groups which could potentially lead to bias of analysis. 
Although we have attempted to correct for the time taken to reach hypothermia by comparing pre-randomisation values with the different time periods, we must acknowledge that the mean time to target temperature was approximately 7 hours. Given that early initiation of TH is considered beneficial in improving efficacy, it could be that a greater decrease in both ICP and PbtO2 would have been seen in the intervention group if the time to reach target temperature was reduced. 
Finally, it should be noted that there were missing data. For example, data was not recorded due to a faulty connection attached to the PbtO2 monitor or a connection accidentally detached. Some of the data were missing in a non-random manner. An example is missing ICP and PbtO2 data when patients were transferred to the CT scanner because monitors were detached to facilitate patient transfer. Due to the small sample size and relatively small amount of data missing, statistical models to analyse the effect of missing data were not performed. The most apparent effect of the missing data is seen when analysing PbtO2 at Time 0 in both the control and intervention groups as described above.  
Conclusion
Therapeutic hypothermia is an effective addition to the management of intracranial hypertension and could potentially reduce the number of hyperosmolar therapies required. It remains to be seen whether the use of TH, titrated to reduce ICP, will result in improved outcomes in patients following TBI. TH below 35°C could reduce oxygen delivery more than oxygen demand leading to reduced cerebral oxygenation and it is unclear why some patients exhibit a greater decrease in PbtO2 than others. Further analysis of patients enrolled on the Eurotherm3235 trial is required to assess the effects of TH on PbtO2. 
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